| Primary |
| Multiple Sclerosis |
82.8% |
| Relapsing-remitting Multiple Sclerosis |
4.5% |
| Pain |
2.5% |
| Hypertension |
1.3% |
| Muscle Spasticity |
1.2% |
| Depression |
1.2% |
| Multiple Sclerosis Relapse |
0.8% |
| Muscle Spasms |
0.8% |
| Fatigue |
0.5% |
| Migraine |
0.5% |
| Back Pain |
0.5% |
| Convulsion |
0.4% |
| Epilepsy |
0.4% |
| Irritable Bowel Syndrome |
0.4% |
| Neuralgia |
0.4% |
| Paraesthesia |
0.4% |
| Urinary Tract Disorder |
0.4% |
| Clinically Isolated Syndrome |
0.3% |
| Diabetes Mellitus |
0.3% |
| Sleep Disorder |
0.3% |
|
| Multiple Sclerosis Relapse |
14.1% |
| Injection Site Erythema |
6.3% |
| Injection Site Pain |
6.0% |
| Pain |
6.0% |
| Fatigue |
5.9% |
| Hypoaesthesia |
5.1% |
| Influenza Like Illness |
4.6% |
| Visual Impairment |
4.6% |
| Malaise |
4.5% |
| Muscular Weakness |
4.4% |
| Vision Blurred |
4.4% |
| Pyrexia |
4.2% |
| Tremor |
4.1% |
| Weight Increased |
4.1% |
| Depression |
3.7% |
| Headache |
3.7% |
| Nausea |
3.7% |
| Vomiting |
3.7% |
| Chills |
3.5% |
| Dizziness |
3.5% |
|
| Secondary |
| Multiple Sclerosis |
72.5% |
| Relapsing-remitting Multiple Sclerosis |
6.9% |
| Hypertension |
5.4% |
| Paraesthesia |
2.8% |
| Pain |
1.5% |
| Depression |
1.3% |
| Back Pain |
1.1% |
| Fatigue |
1.0% |
| Secondary Progressive Multiple Sclerosis |
1.0% |
| Muscle Spasticity |
0.9% |
| Muscle Spasms |
0.8% |
| Sleep Disorder |
0.8% |
| Cardiac Disorder |
0.7% |
| Trigeminal Neuralgia |
0.7% |
| Irritable Bowel Syndrome |
0.5% |
| Upper Respiratory Tract Infection |
0.5% |
| Influenza Immunisation |
0.4% |
| Influenza Like Illness |
0.4% |
| Multiple Sclerosis Relapse |
0.4% |
| Premedication |
0.4% |
|
| Weight Increased |
8.6% |
| Multiple Sclerosis Relapse |
6.8% |
| Pain |
6.8% |
| Injection Site Pain |
6.4% |
| Pyrexia |
6.4% |
| Injection Site Erythema |
5.6% |
| Somnolence |
5.3% |
| Headache |
4.9% |
| Weight Decreased |
4.9% |
| Dyspnoea |
4.5% |
| Influenza Like Illness |
4.5% |
| Sneezing |
4.5% |
| Vision Blurred |
4.5% |
| Dizziness |
4.1% |
| Injection Site Haematoma |
4.1% |
| Nausea |
4.1% |
| Chills |
3.8% |
| Feeling Abnormal |
3.4% |
| Malaise |
3.4% |
| Muscular Weakness |
3.4% |
|
| Concomitant |
| Multiple Sclerosis |
27.0% |
| Breast Cancer |
14.3% |
| Metastases To Lung |
6.3% |
| Pain |
6.3% |
| Product Used For Unknown Indication |
6.3% |
| Premedication |
4.8% |
| Supplementation Therapy |
4.8% |
| Anxiety |
3.2% |
| Depression |
3.2% |
| Hot Flush |
3.2% |
| Insomnia |
3.2% |
| Neoplasm Malignant |
3.2% |
| Relapsing-remitting Multiple Sclerosis |
3.2% |
| Back Pain |
1.6% |
| Blood Cholesterol Increased |
1.6% |
| Bone Density Abnormal |
1.6% |
| Breast Cancer Recurrent |
1.6% |
| Dyspnoea |
1.6% |
| Fatigue |
1.6% |
| Hypertension |
1.6% |
|
| Fatigue |
11.1% |
| Weight Decreased |
11.1% |
| Abdominal Pain Upper |
5.6% |
| Flatulence |
5.6% |
| Injection Site Erythema |
5.6% |
| Injection Site Reaction |
5.6% |
| Liver Injury |
5.6% |
| Multiple Sclerosis Relapse |
5.6% |
| Paraesthesia |
5.6% |
| Pyrexia |
5.6% |
| Sensory Disturbance |
5.6% |
| Type 2 Diabetes Mellitus |
5.6% |
| Urine Odour Abnormal |
5.6% |
| Visual Impairment |
5.6% |
| Vomiting |
5.6% |
| Weight Increased |
5.6% |
|
